Announcements Trials
Browse Landscape

Phase

Phase 1 4

Status

Terminated 2Completed 2

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Tumor-Agnostic 4

Conditions

Neoplasms 4Breast Neoplasms 2Sarcoma 1Non-Squamous Non-Small Cell Lung Cancer 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 133Gemcitabine 101Paclitaxel 100Carboplatin 84Nivolumab 66Docetaxel 62Bevacizumab 62Cisplatin 57Pemetrexed 50Fluorouracil 49Cyclophosphamide 41Cetuximab 41trametinib 38venetoclax 37Leucovorin 37Irinotecan 37Sorafenib 35Capecitabine 35Ipilimumab 33Dexamethasone 32atezolizumab 31Erlotinib Hydrochloride 28130-nm albumin-bound paclitaxel 28Drug Therapy 27Epoetin Alfa 26Doxorubicin 25Oxaliplatin 24Albumin-Bound Paclitaxel 24Prednisone 23Rituximab 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × Neoplasms × RG-1507 monoclonal antibody × Clear all
NCT00400361 2016-11-02

A Multiple Ascending Dose Study of R1507 in Patients With Advanced Solid Tumors.

Hoffmann-La Roche

Phase 1 Completed
98 enrolled
Tumor-Agnostic

Neoplasms

NCT00811993 2016-11-02

A Study of R1507 in Combination With Multiple Standard Chemotherapy Treatments in Patients With Advanced Solid Tumors

Hoffmann-La Roche

Phase 1 Terminated
104 enrolled
Tumor-Agnostic

Neoplasms

NCT00985374 2016-11-02

A Multiple Ascending Dose Study of the mTOR Inhibitor (RAD001) in Combination With R1507 in Patients With Advanced Solid Tumors

Hoffmann-La Roche

Phase 1 Terminated
11 enrolled
Tumor-Agnostic

Neoplasms

NCT00560144 2016-11-01

A Multiple Ascending Dose Study of R1507 in Children and Adolescents With Advanced Solid Tumors.

Hoffmann-La Roche

Phase 1 Completed
34 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡